Mopetia (Paliperidone)

Paliperidone, the active ingredient in Mopetia, is an atypical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia, schizoaffective disorder, and for maintenance therapy in patients with schizophrenia. GNH USA supplies Mopetia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic that acts on dopamine and serotonin pathways to manage serious mental health conditions. - Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Schizoaffective disorder: helps stabilize mood and psychotic features. - Maintenance treatment of schizophrenia: provides long‑term control of symptom recurrence.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity. Common Side Effects: - Akathisia: feeling of inner restlessness. - Weight gain: increase in body mass. - Somnolence: drowsiness or sleepiness. - Hyperprolactinemia: elevated prolactin levels. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: involuntary, repetitive movements. - Seizures: risk of convulsive episodes. - Orthostatic hypotension: sudden drop in blood pressure upon standing. - Agranulocytosis: severe reduction in white blood cells. - Cardiac arrhythmias: abnormal heart rhythms.

Before initiating therapy with Paliperidone, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate for QT prolongation risk. - Metabolic monitoring: track weight, glucose, and lipid levels. - Movement disorders: watch for signs of tardive dyskinesia. - Prolactin elevation: monitor for galactorrhea or menstrual changes. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone can interact with other medicines, altering its effectiveness or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce plasma levels. - QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increase risk of cardiac arrhythmias. Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise paliperidone concentrations. - Anticholinergic drugs: can exacerbate constipation and dry mouth. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensives: potential additive effect on blood pressure lowering.